Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Recent developments in migraine treatment

Chia-Chun Chiang, MD, Mayo Clinic, Rochester, MN, discusses recent developments in migraine treatment. In the past four years, nine new migraine-specific medicines have become available. This includes one ditan, a serotonin agonist for acute migraine treatment, four CGRP monoclonal antibodies used for preventive treatment of migraines, and four gepants. These gepants include ubrogepant for acute migraine treatment, rimegepant for acute and preventive migraine treatment, atogepant, which is FDA-approved for preventive treatment of episodic and chronic migraine, and zavegepant, an FDA-approved nasal spray for acute migraine treatment. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: Satsuma Pharmaceuticals